I agree that this site is using cookies. You can find further informations here.
X
Gomez-Cadena, Alejandra
267  results:
Search for persons X
?
1

Randomized double-blind clinical study in patients with COV..:

Urueña, Claudia ; Ballesteros-Ramírez, Ricardo ; Gomez-Cadena, Alejandra...
Frontiers in Medicine.  9 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
2

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions:

Ercolano, Giuseppe ; Gomez-Cadena, Alejandra ; Dumauthioz, Nina...
Nature Communications.  12 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
3

An Immunomodulatory Gallotanin-Rich Fraction From Caesalpin..:

Lasso, Paola ; Gomez-Cadena, Alejandra ; Urueña, Claudia...
Frontiers in Immunology.  11 (2020)  - p. , 2020
Link: https://doi.org/10.3389/..
 
?
4

Immune system activation by natural products and complex fr..:

Gomez-Cadena, Alejandra ; Barreto, Alfonso ; Fioretino, Susana.
Cell Stress.  4 (2020)  7 - p. 154-166 , 2020
Link: https://doi.org/10.15698..
 
?
5

Severe COVID-19 patients exhibit an ILC2 NKG2D+ population ..:

Gomez-Cadena, Alejandra ; Spehner, Laurie ; Kroemer, Marie...
Cellular & Molecular Immunology.  18 (2020)  2 - p. 484-486 , 2020
Link: https://doi.org/10.1038/..
 
?
6

Peripheral Innate Lymphoid Cells Are Increased in First Lin..:

Loyon, Romain ; Jary, Marine ; Salomé, Bérengère...
Frontiers in Immunology.  10 (2019)  - p. , 2019
Link: https://doi.org/10.3389/..
 
?
7

CD56 as a marker of an ILC1-like population with NK cell pr..:

Salomé, Bérengère ; Gomez-Cadena, Alejandra ; Loyon, Romain...
Blood Advances.  3 (2019)  22 - p. 3674-3687 , 2019
Link: https://doi.org/10.1182/..
 
?
8

Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol..:

Lasso, Paola ; Gomez-Cadena, Alejandra ; Urueña, Claudia...
Frontiers in Oncology.  8 (2018)  - p. , 2018
Link: https://doi.org/10.3389/..
 
?
9

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an imm..:

Trabanelli, Sara ; Chevalier, Mathieu F. ; Martinez-Usatorre, Amaia...
Nature Communications.  8 (2017)  1 - p. , 2017
Link: https://doi.org/10.1038/..
 
?
10

Randomized double-blind clinical study in patients with COV..:

Urueña, Claudia ; Ballesteros-Ramírez, Ricardo ; Gomez-Cadena, Alejandra...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494348/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions:

Ercolano, Giuseppe ; Gomez-Cadena, Alejandra ; Dumauthioz, Nina...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100153/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
12

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions:

Ercolano, Giuseppe ; Gomez-Cadena, Alejandra ; Dumauthioz, Nina...
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-021-22764-2.  , 2021
Link: https://hdl.handle.net/2..
 
?
13

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions:

Ercolano, Giuseppe ; Gomez-Cadena, Alejandra ; Dumauthioz, Nina...
https://boris.unibe.ch/156316/.  , 2021
Link: https://boris.unibe.ch/1..
 
?
14

Severe COVID-19 patients exhibit an ILC2 NKG2D(+) populatio..:

Gomez-Cadena, Alejandra ; Spehner, Laurie ; Kroemer, Marie...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734385/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
15

CD56 as a marker of an ILC1-like population with NK cell pr..:

Salomé, Bérengère ; Gomez-Cadena, Alejandra ; Loyon, Romain...
info:eu-repo/semantics/altIdentifier/pmid/31765481.  , 2019
Link: http://hdl.handle.net/24..
 
1-15